RenovoRx Inc (RNXT)

Name: RenovoRx Inc (RNXT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: RenovoRx Inc (RNXT)

Stock Card

$1.60

$0.12 (8.20%)

As on 28-Aug-2026 13:40EDT

Market cap

$60 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

P/B Ratio

6.6

Div. Yield

0 %

RenovoRx Inc (RNXT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.48 High: 1.64

52 Week Range

Low: 0.70 High: 1.64

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.3 %
ROCE

-- %
Industry P/E

44.46
EV/EBITDA

-4.7
Debt to Equity

0
Book Value

$--
EPS

$-0.3
Face value

--
Shares outstanding

45,129,508

5 Years Aggregate

CFO

$-31.86 Mln

EBITDA

$-34.10 Mln

Net Profit

$-35.26 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
RenovoRx Inc (RNXT)	90.6	65.9	71.9	73.2	-1.8	-27.0	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
RenovoRx Inc (RNXT)	-34.9	-43.4	-2.6	-51.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
RenovoRx Inc (RNXT)	1.6	59.6	2.0	-12.3	-643.9	-170.6	--	6.6
10X Genomics Inc (TXG)	61.9	8,484.6	616.9	-75.1	1.7	-9.3	--	10.1
Avantor (AVTR)	14.5	9,638.1	6,561.1	-578.0	-4.5	-10.3	--	1.7
Bio-Rad Laboratories	365.1	9,761.6	2,589.3	222.4	-6.0	3	44.5	1.3
Bruker (BRKR)	57.5	9,074.5	3,499.6	-71.2	0.5	-3.2	--	3.8
Glaukos Corp (GKOS)	180.0	10,905.5	612.8	-188.1	-30.6	-28.1	--	16.4
Lantheus Holdings (LNTH)	100.5	6,525.3	1,556.3	275.3	24.6	22.9	24	5.0
Penumbra (PEN)	321.8	12,752.7	1,504.9	160.6	13.6	10.9	79.4	8.4
Repligen (RGEN)	178.2	10,222.2	785.1	41.5	9.9	2	251.6	4.8
Smith & Nephew SNATS - ADR	28.9	12,153.4	6,164.0	625.0	13.0	11.8	19.9	2.4

Shareholding Pattern

View Details

About RenovoRx Inc (RNXT)

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which... is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California. Read more

Founder, Chairman of Board & Chief Medical Officer

Dr. Ramtin Agah M.D.
Founder, Chairman of Board & Chief Medical Officer

Dr. Ramtin Agah M.D.
Headquarters

Mountain View, CA
Website

https://renovorx.com

FAQs for RenovoRx Inc (RNXT)

What is the current share price of RenovoRx Inc (RNXT) Today?

The share price of RenovoRx Inc (RNXT) is $1.60 (NASDAQ) as of 28-Aug-2026 13:40 EDT. RenovoRx Inc (RNXT) has given a return of -1.78% in the last 3 years.

What is the current PB & PE ratio of RenovoRx Inc (RNXT)?

Since, TTM earnings of RenovoRx Inc (RNXT) is negative, P/E ratio is not available.
The P/B ratio of RenovoRx Inc (RNXT) is 6.63 times as on 21-Aug-2026, a 73 premium to its peers’ median range of 3.84 times.

PE & PB ratio at the end of financial year.